SCHEMBL24366369

SCHEMBL24366369

Cc1ccc(C2=CCCCC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.53
CCR1 P32246 1/20 0.52
CCR5 P51681 1/20 0.52
CCR8 P51685 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
PSMB5 P28074 7/20 0.44
METAP2 P50579 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2A6 P11509 1/20 0.39
PSMB1 P20618 1/20 0.37
ATR Q13535 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30469661 1.00 TDP1 (0.53) TDP1CCR1CCR5CCR8HDAC6
SCHEMBL18088962 0.85 CCR1 (0.60) TDP1CCR1CCR5CCR8HDAC6
SCHEMBL31307013 0.79 TDP1 (0.53) TDP1RAB9ANPC1CASP3SENP8
SCHEMBL21988063 0.79 TDP1 (0.53) TDP1RAB9ANPC1CASP3SENP8
SCHEMBL3143646 0.79 TDP1 (0.53) TDP1RAB9ANPC1CASP3SENP8
SCHEMBL18015411 0.79 TDP1 (0.53) TDP1RAB9ANPC1CASP3SENP8
SCHEMBL13490344 0.75 TDP1 (0.56) TDP1RAB9ANPC1CASP3SENP8
SCHEMBL11983533 0.74 CCR1 (0.53) TDP1CCR1CCR5CCR8RAB9A
SCHEMBL10991732 0.72 PSMB5 (0.47) TDP1PSMB5PSMB1
SCHEMBL13490567 0.72 CCR1 (0.48) CCR1CCR5CCR8HDAC6METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TDP1 2792/4885CCR1 311/4885CCR5 486/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TDP1 2792/4885CCR1 311/4885CCR5 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.